Imaging technology might help doctors determine best treatment for Crohn's disease patients

It's difficult for doctors to tell whether a patient with Crohn's disease has intestinal fibrosis, which requires surgery, or inflammation, which can be treated with medicine. A new imaging method might make that task easier, according to a U-M-led study.

Ultrasound elasticity imaging, or UEI, could allow doctors to noninvasively make the distinction between inflammation and , allowing patients to receive more appropriate and timely care. The study was published in the September edition of Gastroenterology.

Crohn's disease patients suffer from of the intestines, which over time can cause scar tissue to form, resulting in intestinal fibrosis.

Patients with usually are treated with medicines that suppress their immune system, while patients with fibrosis are treated surgically. Because current diagnostic tests, including CT scans and MRIs, cannot detect the difference between the two conditions, many patients with fibrosis are often initially treated with immune system-suppressing drugs, which are expensive and are unlikely to help.

"These therapies are potent, costly and carry risk," says Ryan Stidham, M.D., clinical lecturer in the Department of Internal Medicine. "And for patients with fibrosis, such treatment might be for naught."

Inflamed is softer than fibrotic tissue, which is hard and thick. The new method uses ultrasound to measure the relative hardness and thickness of tissue inside the body, potentially allowing doctors to differentiate between the two conditions without performing surgery. In animal models, UEI was able to accurately tell the difference between inflamed tissue and .

"The goal of this study is to have technology that can make the distinction between fibrosis and inflammation," says Stidham, the lead author of the study. "We want to know if it's worth it to push , or if a person is destined for surgery."

The researchers also found that UEI was capable of differentiating between fibrotic and unaffected intestine in a pilot human study. Patients already scheduled for surgical treatment underwent UEI assessment prior to surgery, and fibrotic strictures were identified in each case.

Stidham says the next step in the group's research is a long-term human clinical trial, beginning this winter. If UEI is able to accurately assess a patient's condition, doctors will be able to more efficiently treat Crohn's disease patients suffering from inflammation or fibrosis.

"UEI has great potential to provide a clear measurement that helps clinicians judge whether medical or surgical management is best for the individual patient earlier in their disease course." Stidham says.

More information: Gastroenterology, DOI:10.1053/j.gastro.2011.07.027 ; published online July 25, 2011. "Ultrasound Elasticity Imaging for Detecting Intestinal Fibrosis and Inflammation in Rats and Humans With Crohn's Disease"

Related Stories

Scarred lungs leave trail of beta arrestins

date Mar 28, 2011

Targeting a family of signaling proteins called beta arrestins may stop the life-threatening scarring and thickening of lungs associated with pulmonary fibrosis, reports a new Science study in mice.

Cancer drug may also work for scleroderma

date Sep 22, 2011

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

Recommended for you

Score IDs patients with upper extremity DVT at low risk

date 15 hours ago

(HealthDay)—For patients with upper-extremity deep vein thrombosis (DVT), six easily available factors can be used to create a score that identifies those at low risk of adverse events during the first ...

Combined drug treatment combats kidney disease

date May 29, 2015

A recent discovery by drug researchers whereby coupling specific cell membrane receptors has altered kidney cell function has triggered a re-think of how to treat chronic kidney disease (CKD) more effectively.

Active substance targeting dreaded hospital germs

date May 29, 2015

In the German Center for Infection Research (DZIF), scientists have conducted clinical studies on an active substance against the dreaded hospital pathogen Staphylococcus aureus: a highly effective protein from bacteriophages ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.